Research Article
Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients
Table 1
Baseline characteristics and rate of viral suppression by darunavir dose.
| | All patients | DRV 1,200 mg daily | DRV 600 mg twice daily | DRV 800 mg daily | value |
| | 135 | 28 | 65 | 42 | | Age, yr, median (IQR) | 47 (43–52) | 48 (42–51) | 46 (42–51) | 49 (44–54) | 0.174 | Race/ethnicity | | | | | 0.198 | African American (%) | 48.1 | 60.7 | 36.9 | 57.1 | | Caucasian (%) | 33.3 | 25 | 38.5 | 31 | | Hispanic (%) | 17 | 14.3 | 21.5 | 11.9 | | Other/unknown (%) | 1.5 | 0 | 3.1 | 0 | | Baseline viral load | | | | | 0.197 | <1,000 copies/mL (%) | 43 | 45.2 | 33.8 | 45.2 | | 1,000–99,999 copies/mL (%) | 40.7 | 40.5 | 46.2 | 40.5 | | ≥100,000 copies/mL (%) | 16.3 | 14.3 | 20 | 14.3 | | CD4+ cells/mL, mean (SD) | 343.3 | 399.8 (355.1) | 259.4 (229.6) | 435.6 (283.5) | 0.003 | Concomitant ARVs, mean (SD) | 2.2 | 1.86 (1.01) | 2.55 (1.00) | 1.93 (0.71) | <0.001 | Baseline resistance | | | | | | Baseline resistance testing available () | 109/135 | 20/28 | 57/65 | 32/42 | | Total DRV RAMs at baseline | 72 | 5 | 66 | 1 | <0.001 | Baseline DRV RAMs, median (range) | 0 (0–4) | 0 (0–3) | 1 (0–4) | 0 (0-1) | <0.001 | Patients with ≥1 documented DRV RAM (%) | 28.9 | 10.7 | 53.8 | 2.4 | <0.001 | Endpoints | | | | | | <50 copies/mL, 24 weeks (%) | 49.6 | 53.6 | 52.3 | 42.9 | 0.568 | <50 copies/mL, 48 weeks (%) | 48.4 | 45.8 | 49.2 | 48.5 | 0.960 |
|
|